Exelgen Announces Partnerships with Two Leading European Biotechnology Companies

RICHMOND, Va. & BUDE, England--(BUSINESS WIRE)--Exelgen Ltd. (formerly Tripos Discovery Research), a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market: CBTE) and a leading provider of drug discovery chemistry services and small molecule products, today announced significant new collaborations with two prominent European-based Biotechnology companies. Because of the proprietary nature of the collaborations both companies have declined to be identified or disclose the contract values at this time. One company is a long standing client, the other a new client.

Back to news